Sign in

You're signed outSign in or to get full access.

BB

Beta Bionics, Inc. (BBNX)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 revenue grew 145% year over year to $20.4M, with gross margin at 57.2%; net loss was $18.1M as pharmacy mix began to rise and operating expenses expanded with growth investments .
  • Versus S&P Global consensus, BBNX delivered a modest revenue beat ($20.44M vs. $20.19M*) but a significant EPS miss (−$2.72 actual vs. −$1.22*) as mix and one‑time items weighed on GAAP EPS *.
  • Management introduced FY2025 guidance: revenue $80–$85M, >20% of new starts through pharmacy, and ≥50% gross margin, citing tailwinds from Libre 3 Plus integration, Color iLet, and Bionic Circle app .
  • Strategic catalysts highlighted: first U.S. pump integration with Abbott FreeStyle Libre 3 Plus (Oct 30, 2024), expanding pharmacy formulary access (Prime Therapeutics effective Feb 1, 2025), and IPO proceeds of ~$206M to fund patch pump and bihormonal programs .

What Went Well and What Went Wrong

What Went Well

  • Q4 revenue and installed base inflected: net sales $20.4M (+145% YoY); installed base 15,298 (+564% YoY), with 4,084 new patient starts and ~70% from MDI—evidence of market expansion beyond traditional pump users .
  • Commercial and product momentum: Color iLet (Oct ’24), Bionic Circle (Sep ’24), and first‑to‑market Libre 3 Plus integration (Nov ’24) began contributing; “we’re excited for the impact they may have moving forward” (CEO/CFO) .
  • Pharmacy channel scaling improves access and long‑term unit economics; CFO: pharmacy “is our preferred revenue channel…most profitable in the medium and long term,” despite near‑term revenue/GM drag .

What Went Wrong

  • EPS miss and sustained losses: GAAP EPS −$2.72 vs. −$1.22* consensus; Q4 operating loss −$13.0M (−64% of sales), adjusted EBITDA −$11.3M; full‑year net loss −$54.8M as opex grew with commercial scale and a $3M Xeris milestone .
  • Gross margin compression vs. prior year: Q4 GM 57.2% (−344 bps YoY) with management reiterating pharmacy mix headwind near term (becomes accretive beyond ~11 months per patient) .
  • Mix shift weighs on revenue cadence: management warned Q1 sequential step‑down vs. Q4 due to seasonality and pharmacy mix ramp; analysts probed visibility and share gains, but CFO declined to quantify quarterly revenue or market share .

Financial Results

Quarterly Performance and Trend (oldest → newest)

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$15.0 $16.7 $20.4
Gross Margin (%)54% 53% 57%
Adjusted EBITDA ($USD Millions)$(10.0) $(8.7) $(11.3)
New Patient Starts (units)3,133 3,180 4,084

Q4 2024 Actual vs. S&P Global Consensus

MetricActualConsensusBeat/Miss
Revenue ($USD Millions)$20.44 $20.19*+$0.25M (Beat)*
EPS (Primary, $USD)−$2.72 −$1.22*−$1.50 (Miss)*

Values marked with * retrieved from S&P Global.

Segment/Channel Breakdown

Channel / ProductQ4 2023 ($000)Q4 2024 ($000)
DME – iLet$7,145 $13,613
DME – Single-use$803 $4,450
Total DME$7,948 $18,063
Pharmacy – iLet$222 $385
Pharmacy – Single-use$180 $1,992
Total Pharmacy$402 $2,377
Total Net Sales$8,350 $20,440

KPIs

KPIQ4 2023Q4 2024
Installed Customer Base (rolling 4‑yr)2,304 15,298
New Patient Starts1,818 4,084
New Patient Starts from MDI (%)55% 70%

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2025n/a (initial guide) $80–$85M Introduced
New Patient Starts via Pharmacy (%)FY 2025n/a >20% Introduced
Gross Margin (%)FY 2025n/a ≥50% Introduced

Management also outlined expected revenue cadence: Q1 step‑down vs. Q4 due to seasonality and pharmacy mix ramp; heavier weighting in H2 as new territories mature and seasonality benefits Q4 .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q‑2 and Q‑1)Current Period (Q4 2024)Trend
Pharmacy channel strategyPharmacy mix: mid‑single digit (H1), high‑single digit (Q3) of new starts; long‑term accretive economics Low‑teens % in Q4; >20% guided for FY25; Prime Therapeutics formulary effective Feb 1, 2025 Increasing mix; near‑term drag on revenue/GM, long‑term accretive
Product launchesBionic Circle (Sep ’24), Color iLet (Oct ’24) started ramping First U.S. Libre 3 Plus integration in Nov ’24; tailwinds expected through 2025 Strengthening product stack; accessibility and ease‑of‑use
Tariffs/macroNot emphasized priorTariff exposure de minimis; Nairobi Protocol exemptions; impact nominal even if changed Limited macro headwind
R&D – Patch pumpTarget commercialization by end of 2027; no clearance timing guided Reiterated timeline; investment from IPO proceeds planned On track; funding secured
R&D – BihormonalPK/PD bridging; 1‑yr drug pivotal + 6‑mo device pivotal; 510(k) + 505(b)(2) NDA contemplated Exclusive Xeris glucagon; $3M milestone; path to market reiterated Advancing toward pivotal
Type 2 off‑label / PCP>20% of H2 ’24 starts were Type 2; pharmacy simplifies prescribing; PCP channel attractive Continuing off‑label organic adoption; pursuing label expansion (timing not disclosed) Building case for T2D expansion

Management Commentary

  • CEO on 2024 momentum: “We ended the year with over 15,000 users… progressed in our efforts to secure pharmacy channel coverage… and advanced our patch and bihormonal pipeline programs” .
  • CFO on economics: “Pharmacy…is accretive to our financials on the top and bottom line in the medium and long term… drag on revenue and gross margin in the near term” .
  • CEO on differentiation: “Our product starts up based on weight and then learns and adapts to you… we see a pretty big chasm between ease of use aspects of what we’re up to and [competitors]” .

Q&A Highlights

  • Pharmacy visibility and cadence: CFO affirmed visibility into early‑2025 pharmacy traction and reiterated revenue weighting similar to 2024 with Q1 step‑down; declined to quantify Q1 revenue or market share .
  • Patch pump timing: still targeting commercialization by end of 2027; no specific clearance timeline guided .
  • Competitive algorithms/ease‑of‑use: management emphasized fully adaptive dosing initiated by weight, positioning vs. competitors’ setup simplifications .
  • Type 2 adoption and PCP: organic off‑label use noted; pharmacy reduces burden for PCP prescribing; label expansion planned (timing not disclosed) .
  • Patient economics: pharmacy out‑of‑pocket typically ~$0–$100 upfront and ~$25/month vs. DME’s larger upfront and ~$35/month supplies; company revenue ~$450/month in pharmacy .

Estimates Context

  • Q4 2024: revenue beat modestly ($20.44M vs. $20.19M*), while EPS missed (−$2.72 vs. −$1.22*), driven by pharmacy mix headwinds, operating expense growth, and fair value warrant changes/non‑GAAP adjustments *.
  • Prior quarters: Q2/Q3 2024 actual revenues were $15.0M and $16.7M respectively; consensus history limited; analysts likely to recalibrate near‑term gross margin trajectories given FY25 ≥50% GM guide and pharmacy mix ramp .

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • Channel mix transition is the narrative: expect near‑term revenue/GM headwinds from pharmacy adoption, with improved LT economics and access—model elevated recurring supplies and better cohort retention beyond ~11 months .
  • Product stack strengthening: Color iLet, Bionic Circle, and Libre 3 Plus integration materially enhance ease‑of‑use and caregiver visibility—supporting market expansion into MDI and PCP channels .
  • 2025 setup: revenue $80–$85M, ≥50% GM, and >20% pharmacy new starts; cadence weighted to H2—position long exposure around formulary activation and territory maturation .
  • R&D optionality: funded roadmap for patch (end‑2027 commercialization target) and bihormonal (drug/device pivotal path) offers medium‑term catalysts—track trial initiations and regulatory filings .
  • T2D expansion: early off‑label adoption suggests potential TAM unlock post‑label expansion; pharmacy channel and simplicity may drive PCP uptake .
  • Risk monitor: opex scaling, GAAP EPS volatility (warrants), and execution on pharmacy activation at health plans; macro tariffs currently de minimis .

Sources

  • Q4 2024 8‑K press release and exhibits: .
  • Q4 2024 earnings call transcript: –.
  • Q4 2024 earnings slides: quarterly tables and economics: .
  • Libre 3 Plus PR (Oct 30, 2024): .

Values marked with * retrieved from S&P Global.